{
    "clinical_study": {
        "@rank": "144749", 
        "acronym": "BEACON", 
        "arm_group": [
            {
                "arm_group_label": "400 \u00b5g Brimonidine Implant", 
                "arm_group_type": "Experimental", 
                "description": "400 \u00b5g brimonidine implant in the study eye on Day 1, and every 3 months through Month 21."
            }, 
            {
                "arm_group_label": "Sham", 
                "arm_group_type": "Sham Comparator", 
                "description": "Sham treatment with needleless applicator (no implant) to the study eye on Day 1, and every 3 months through Month 21."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will assess the safety and efficacy of the brimonidine intravitreal implant in\n      patients with geographic atrophy due to age-related macular degeneration."
        }, 
        "brief_title": "A Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic Atrophy Secondary to Age-related Macular Degeneration", 
        "completion_date": {
            "#text": "October 2018", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Geographic Atrophy", 
            "Macular Degeneration"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Macular Degeneration", 
                "Atrophy", 
                "Geographic Atrophy"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Geographic atrophy due to age-related macular degeneration in the study eye\n\n          -  Visual acuity better than or equal to 20/62 in the study eye and 20/200 in the fellow\n             eye\n\n        Exclusion Criteria:\n\n          -  Cataract surgery or Laser-Assisted in situ Keratomileusis (LASIK) in the study eye in\n             the last 3 months\n\n          -  Infections in either eye in the last 3 months"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "55 Years"
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 12, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02087085", 
            "org_study_id": "190342-038", 
            "secondary_id": "2013-003320-36"
        }, 
        "intervention": [
            {
                "arm_group_label": "400 \u00b5g Brimonidine Implant", 
                "description": "400 \u00b5g brimonidine implant in the study eye on Day 1, and every 3 months through Month 21.", 
                "intervention_name": "400 \u00b5g Brimonidine Implant", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Sham", 
                "description": "Sham treatment with needleless applicator (no implant) to the study eye on Day 1, and every 3 months through Month 21.", 
                "intervention_name": "Sham", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Brimonidine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 7, 2014", 
        "link": {
            "description": "More Information", 
            "url": "http://www.allerganclinicaltrials.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Abilene", 
                        "country": "United States", 
                        "state": "Texas"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Arlington", 
                        "country": "United States", 
                        "state": "Texas"
                    }
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "email": "clinicaltrials@allergan.com", 
            "last_name": "Allergan Inc."
        }, 
        "overall_official": {
            "affiliation": "Allergan", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change from Baseline in Atrophic Lesion Area in the Study Eye", 
            "safety_issue": "No", 
            "time_frame": "Baseline, Month 24"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02087085"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from Baseline in Retinal Sensitivity in the Study Eye", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Month 24"
            }, 
            {
                "measure": "Change from Baseline in Low Luminance Best Corrected Visual Acuity (BCVA) in the Study Eye", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Month 24"
            }, 
            {
                "measure": "Change from Baseline in BCVA in the Study Eye", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Month 24"
            }
        ], 
        "source": "Allergan", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Allergan", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}